Skip to main content
PortfolioPoseida Therapeutics, Inc.

Poseida Therapeutics: FDA Grants Poseida’s P-BCMA-101 Regenerative Medicine Advanced Therapy (RMAT) Status for Treatment of Multiple Myeloma

By November 19, 2018March 15th, 2021No Comments